Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report.

Ito A, Hisano M, Takahashi M, Komine N, Abe T, Obara W.

Urol Case Rep. 2019 Oct 15;28:101048. doi: 10.1016/j.eucr.2019.101048. eCollection 2020 Jan.

2.

Corrigendum to: Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program.

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M.

Jpn J Clin Oncol. 2019 Nov 6. pii: hyz143. doi: 10.1093/jjco/hyz143. [Epub ahead of print] No abstract available.

PMID:
31693139
3.

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.

Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, Sugiyama T, Oya M, Fujii Y, Obara W, Motzer RJ, Uemura H.

Jpn J Clin Oncol. 2019 Oct 21. pii: hyz132. doi: 10.1093/jjco/hyz132. [Epub ahead of print]

PMID:
31633185
4.

12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population.

Takata R, Takahashi A, Fujita M, Momozawa Y, Saunders EJ, Yamada H, Maejima K, Nakano K, Nishida Y, Hishida A, Matsuo K, Wakai K, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Sasaki M, Shimizu A, Tanno K, Minegishi N, Suzuki K, Matsuda K, Kubo M, Inazawa J, Egawa S, Haiman CA, Ogawa O, Obara W, Kamatani Y, Akamatsu S, Nakagawa H.

Nat Commun. 2019 Sep 27;10(1):4422. doi: 10.1038/s41467-019-12267-6.

5.

Usefulness of a novel classification based on perioperative changes of membranous urethral length using hierarchical cluster analysis of urinary incontinence and overactive bladder symptoms after robot-assisted radical prostatectomy: A prospective observational study.

Onoda M, Haga N, Kurimura Y, Tanji R, Onagi A, Honda R, Matsuoka K, Hoshi S, Koguchi T, Hata J, Sato Y, Akaihata H, Kataoka M, Ogawa S, Obara W, Kojima Y.

Neurourol Urodyn. 2019 Nov;38(8):2200-2208. doi: 10.1002/nau.24117. Epub 2019 Jul 23.

PMID:
31338904
6.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G.

Int J Clin Oncol. 2019 Sep;24(9):1089-1098. doi: 10.1007/s10147-019-01450-w. Epub 2019 Jun 19.

PMID:
31218529
7.

Analysis of Expression Patterns of MicroRNAs That Are Closely Associated With Renal Carcinogenesis.

Shiomi E, Sugai T, Ishida K, Osakabe M, Tsuyukubo T, Kato Y, Takata R, Obara W.

Front Oncol. 2019 May 31;9:431. doi: 10.3389/fonc.2019.00431. eCollection 2019.

8.

Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report.

Ikarashi D, Nakamura Y, Shimodate H, Usui Y, Ujiie T, Obara W.

Urol Case Rep. 2019 Jan 30;24:100839. doi: 10.1016/j.eucr.2019.100839. eCollection 2019 May.

9.

A case of angiosarcomas which occurred in an adrenal gland and spleen synchronously.

Ishii S, Omori S, Uesugi N, Tsuyukubo T, Ito A, Kikuchi D, Onoda M, Takata R, Sugai T, Obara W.

Int Cancer Conf J. 2018 Jul 6;7(4):134-136. doi: 10.1007/s13691-018-0337-y. eCollection 2018 Oct.

10.

Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program.

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M.

Jpn J Clin Oncol. 2019 Aug 1;49(8):772-779. doi: 10.1093/jjco/hyz054.

PMID:
30977820
11.

Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients.

Kanehira M, Takata R, Ishii S, Ito A, Ikarashi D, Matsuura T, Kato Y, Obara W.

Int J Clin Oncol. 2019 Sep;24(9):1099-1104. doi: 10.1007/s10147-019-01445-7. Epub 2019 Apr 10.

PMID:
30972506
12.

[COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].

Ito A, Takata R, Matsuo T, Kimura T, Otsuka K, Ishii S, Tokiwa S, Tanji S, Sugimura J, Omori S, Obara W.

Nihon Hinyokika Gakkai Zasshi. 2018;109(1):35-39. doi: 10.5980/jpnjurol.109.35. Japanese.

13.

Appropriate preoperative membranous urethral length predicts recovery of urinary continence after robot-assisted laparoscopic prostatectomy.

Ikarashi D, Kato Y, Kanehira M, Takata R, Ito A, Onoda M, Kato R, Matsuura T, Iwasaki K, Obara W.

World J Surg Oncol. 2018 Nov 16;16(1):224. doi: 10.1186/s12957-018-1523-2.

14.

A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer.

Kato Y, Zembutsu H, Takata R, Matsuura T, Kato R, Kanehira M, Iwasaki K, Yamada N, Katagiri T, Sugai T, Fujioka T, Nakamura Y, Obara W.

Oncol Lett. 2018 Nov;16(5):5775-5784. doi: 10.3892/ol.2018.9330. Epub 2018 Aug 20.

15.

Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer.

Nakamura R, Kakuhara H, Kikuchi K, Segawa T, Oikawa H, Iwasaki K, Obara W, Ariga H.

Anticancer Res. 2018 Aug;38(8):4827-4831. doi: 10.21873/anticanres.12793.

PMID:
30061255
16.

Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.

Obara W, Hara I, Kato Y, Kato R, Inoue K, Sato F, Mimata H, Nakamura Y, Fujioka T.

Cancer Immunol Immunother. 2018 Sep;67(9):1371-1380. doi: 10.1007/s00262-018-2197-x. Epub 2018 Jul 3.

PMID:
29971464
17.

Relationship between nocturnal polyuria and non-dipping blood pressure in male patients with lower urinary tract symptoms.

Takayama M, Omori S, Iwasaki K, Shiomi E, Takata R, Sugimura J, Abe T, Obara W.

Low Urin Tract Symptoms. 2019 Apr;11(2):O98-O102. doi: 10.1111/luts.12225. Epub 2018 May 29.

PMID:
29845738
18.

[A Case of Renal Pelvic Cancer with Acquired Hemophilia and Leukemoid Reaction].

Ikarashi D, Omori S, Izumida W, Nakamura Y, Abe M, Ujiie T, Obara W.

Hinyokika Kiyo. 2018 Apr;64(4):151-155. doi: 10.14989/ActaUrolJap_64_4_151. Japanese.

19.

Laparoscopic nephrectomy in a patient with severe scoliosis: A case report.

Tamura D, Ito A, Kikuchi D, Tsuyukubo T, Kato R, Kato Y, Konari S, Omori S, Obara W.

Asian J Endosc Surg. 2019 Jan;12(1):122-124. doi: 10.1111/ases.12597. Epub 2018 May 10.

PMID:
29747234
20.

Single-stage laparoscopic surgery for bilateral organ tumors using a transumbilical approach with a zigzag incision: a report of two cases.

Kato Y, Kato R, Takayama M, Ikarashi D, Onoda M, Matsuura T, Kanehira M, Takata R, Baba S, Kimura T, Otsuka K, Sugimura J, Omori S, Sasaki A, Obara W.

BMC Urol. 2018 May 2;18(1):28. doi: 10.1186/s12894-018-0343-6.

21.

Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.

Ikarashi D, Kato Y, Katagiri H, Takahara T, Uesugi N, Shiomi E, Sugimura J, Nitta H, Sugai T, Obara W.

Int J Urol. 2018 Jun;25(6):630-632. doi: 10.1111/iju.13590. Epub 2018 Apr 25.

22.

Pelvic Artery Calcification Score Is a Marker of Vascular Calcification in Male Hemodialysis Patients.

Matsuura T, Abe T, Onoda M, Ikarashi D, Sugimura J, Komaki T, Sasaki N, Takasawa Y, Kato T, Yoshioka K, Ehara S, Obara W.

Ther Apher Dial. 2018 Oct;22(5):509-513. doi: 10.1111/1744-9987.12668. Epub 2018 Mar 30.

PMID:
29600601
23.

Present status and future perspective of peptide-based vaccine therapy for urological cancer.

Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R.

Cancer Sci. 2018 Mar;109(3):550-559. doi: 10.1111/cas.13506. Epub 2018 Feb 15. Review.

24.

Renal pelvic cancer with spleen invasion arising in horseshoe kidney; a case report.

Ito A, Kato Y, Shiomi E, Ishii S, Suzuki M, Omori S, Abe T, Tanji S, Sugai T, Obara W.

Urol Case Rep. 2017 Dec 5;16:123-125. doi: 10.1016/j.eucr.2017.11.031. eCollection 2018 Jan. No abstract available.

25.

Sporadic breast metastasis derived from renal cell carcinoma: A case report.

Ikarashi D, Ishida K, Kashiwaba M, Kato Y, Shiomi E, Takayama M, Komatsu H, Takata R, Ohmori S, Sugai T, Obara W.

Urol Case Rep. 2017 Dec 5;16:126-128. doi: 10.1016/j.eucr.2017.11.032. eCollection 2018 Jan. No abstract available.

26.

Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association.

Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association.

Jpn J Clin Oncol. 2017 Dec 1;47(12):1162-1169. doi: 10.1093/jjco/hyx129.

PMID:
29121328
27.

Current Status of Hepatitis C Virus-Infected Maintenance Hemodialysis Patients in Japan.

Abe T, Oomori S, Obara W.

Ther Apher Dial. 2018 Feb;22(1):58-60. doi: 10.1111/1744-9987.12603. Epub 2017 Oct 26.

PMID:
29071791
28.

Recent progress in immunotherapy for urological cancer.

Obara W, Kato R, Kato Y, Kanehira M, Takata R.

Int J Urol. 2017 Oct;24(10):735-742. doi: 10.1111/iju.13400. Epub 2017 Jun 21. Review.

29.

Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.

Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Mimata H, Sugai T, Nakamura Y, Fujioka T.

Cancer Sci. 2017 Jul;108(7):1452-1457. doi: 10.1111/cas.13278. Epub 2017 Jun 23.

30.

Non-machinery dialysis that achieves blood purification therapy without using full-scale dialysis machines.

Abe T, Onoda M, Matsuura T, Sugimura J, Obara W, Sato T, Takahashi M, Chiba K, Abe T.

J Artif Organs. 2017 Sep;20(3):230-235. doi: 10.1007/s10047-017-0953-x. Epub 2017 Mar 29.

PMID:
28357590
31.

Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.

Kato R, Kato Y, Matsuura T, Kanehira M, Takata R, Obara W.

BMC Cancer. 2017 Mar 23;17(1):214. doi: 10.1186/s12885-017-3205-9.

32.

Efficacy of Everolimus for Treating Renal Angiomyolipoma with Inferior Vena Cava Thrombus Associated with Tuberous Sclerosis: A Case Report.

Ikarashi D, Mue Y, Shiomi E, Takayama M, Kato R, Kato Y, Ishida K, Abe T, Sugai T, Obara W.

Urol Case Rep. 2017 Jan 5;11:11-13. doi: 10.1016/j.eucr.2016.12.003. eCollection 2017 Feb.

33.

A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.

Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T.

Ann Oncol. 2017 Apr 1;28(4):798-803. doi: 10.1093/annonc/mdw675.

PMID:
27998971
34.

Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.

Obara W, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T.

Cancer Immunol Immunother. 2017 Jan;66(1):17-24. doi: 10.1007/s00262-016-1915-5. Epub 2016 Oct 18.

35.

Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma.

Onoda M, Sugimoto R, Uesugi N, Takayama M, Shiomi E, Kato R, Kato Y, Takata R, Omori S, Obara W.

Int Cancer Conf J. 2016 Oct 11;6(1):25-28. doi: 10.1007/s13691-016-0266-6. eCollection 2017 Jan.

36.

[Advancement of examination and diagnosis of prostate cancer: General concept].

Kanehira M, Takata R, Obara W.

Nihon Rinsho. 2016 May 20;74 Suppl 3:271-4. Japanese. No abstract available.

PMID:
27344740
37.

Standardized Prevalence Ratios for Atrial Fibrillation in Adult Dialysis Patients in Japan.

Ohsawa M, Tanno K, Okamura T, Yonekura Y, Kato K, Fujishima Y, Obara W, Abe T, Itai K, Ogasawara K, Omama S, Turin TC, Miyamatsu N, Ishibashi Y, Morino Y, Itoh T, Onoda T, Kuribayashi T, Makita S, Yoshida Y, Nakamura M, Tanaka F, Ohta M, Sakata K, Okayama A.

J Epidemiol. 2016 May 5;26(5):272-6. doi: 10.2188/jea.JE20150077. Epub 2016 Jan 23.

38.

Therapeutic implication of genetic variants of IL13 and STAT4 in airway remodelling with bronchial asthma.

Nakamura Y, Suzuki R, Mizuno T, Abe K, Chiba S, Horii Y, Tsuboi J, Ito S, Obara W, Tanita T, Kanno H, Yamauchi K.

Clin Exp Allergy. 2016 Sep;46(9):1152-61. doi: 10.1111/cea.12710. Epub 2016 May 3.

PMID:
26765219
39.

Neural cell adhesion molecule (CD56)-positive B cell lymphoma of the urinary bladder.

Kawasaki T, Suzuki M, Sato A, Yashima-Abo A, Satoh T, Kato R, Kato Y, Obara W, Shimoyama T, Ishida Y, Sugai T.

J Clin Pathol. 2016 Jan;69(1):89-92. doi: 10.1136/jclinpath-2015-203250. Epub 2015 Sep 21. No abstract available.

PMID:
26391771
40.

[Side effect and supportive care to combination of gemcitabine and cisplatin chemotherapy for the advanced urothelial cancer].

Kato Y, Sato J, Kato R, Takata R, Obara W.

Nihon Rinsho. 2015 Feb;73 Suppl 2:609-13. Japanese. No abstract available.

PMID:
25831832
41.

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.

Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S.

Cancer Sci. 2015 May;106(5):618-26. doi: 10.1111/cas.12646. Epub 2015 Mar 19.

42.

Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population.

Matsuda K, Takahashi A, Middlebrooks CD, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C, Cui R, Figueroa JD, Silverman DT, Rothman N, Namiki M, Tomita Y, Nishiyama H, Kohri K, Deguchi T, Nakagawa M, Yokoyama M, Miki T, Kumon H, Fujioka T, Prokunina-Olsson L, Kubo M, Nakamura Y, Shuin T.

Hum Mol Genet. 2015 Feb 15;24(4):1177-84. doi: 10.1093/hmg/ddu512. Epub 2014 Oct 3.

43.

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.

Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.

PMID:
24688083
44.

Retraction for Akimoto et al., Testis-specific protein on Y chromosome (TSPY) represses the activity of the androgen receptor in androgen-dependent testicular germ-cell tumors.

Akimoto C, Ueda T, Inoue K, Yamaoka I, Sakari M, Obara W, Fujioka T, Nagahara A, Nonomura N, Tsutsumi S, Aburatani H, Miki T, Matsumoto T, Kitagawa H, Kato S.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2398. doi: 10.1073/pnas.1323399111. Epub 2014 Jan 21. No abstract available.

45.

Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan.

Abe T, Kitamura H, Obara W, Matsumura N, Tsukamoto T, Fujioka T, Hara I, Murai S, Shinohara N, Nonomura K.

J Urol. 2014 Apr;191(4):932-6. doi: 10.1016/j.juro.2013.11.004. Epub 2013 Nov 7.

46.

Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan.

Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S; Members of the Japanese Society of Renal Cancer.

BMC Cancer. 2013 Oct 2;13:447. doi: 10.1186/1471-2407-13-447.

47.

Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report and review of the literature.

Kato Y, Konari S, Obara W, Sugai T, Fujioka T.

BMC Urol. 2013 Jul 20;13:36. doi: 10.1186/1471-2490-13-36. Review.

48.

Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.

Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.

Jpn J Clin Oncol. 2013 Feb;43(2):193-9. doi: 10.1093/jjco/hys213. Epub 2012 Dec 28.

PMID:
23275643
49.

Impact of four loci on serum tamsulosin hydrochloride concentration.

Takata R, Matsuda K, Sugimura J, Obara W, Fujioka T, Okihara K, Takaha N, Miki T, Ashida S, Inoue K, Tanikawa C, Shuin T, Sasaki S, Kojima Y, Kohri K, Kubo M, Yamaguchi M, Ohnishi Y, Nakamura Y.

J Hum Genet. 2013 Jan;58(1):21-6. doi: 10.1038/jhg.2012.126. Epub 2012 Nov 15.

PMID:
23151678
50.

Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.

Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T.

Jpn J Clin Oncol. 2012 Jul;42(7):591-600. doi: 10.1093/jjco/hys069. Epub 2012 May 25.

PMID:
22636067

Supplemental Content

Support Center